School of Medicine
Showing 361-380 of 511 Results
-
Matteo Santoro Pharm.D., Ph.D.
Postdoctoral Scholar, Pathology
BioDr. Santoro joined Stanford University in March 2021, focusing his research on Parkinson’s disease, neuronal vulnerability, and identification of therapeutic markers in relation to α-synucleinopathies. Currently under the Supervision of Prof. Thomas Montine, he is working on the development of LRRK2 selective inhibitors. Prior to his arrival at Stanford, he held a position as a clinical monitor at Syneos Health, where he gained key knowledge needed to translate lab-based findings into clinical and commercial applications. Previously, Dr. Santoro held a postdoctoral position at the University of Aberdeen (Scotland, UK), working on amyloid-beta extracts from Alzheimer’s disease patients. During his postdoctoral research, Dr. Santoro designed and optimized a cost-effective and rapid assay for the measurement of toxic amyloid-beta species in human biofluids. In 2017, he obtained his Ph.D. (4-year program) at the University of Aberdeen on Parkinson’s disease (PD), immunology, and behavior. The major findings Ph.D. findings were the following: 1) the characterization of a small protein called HMGB1 as an inflammatory mediator in PD; 2) the motor and non-motor behavioral characterization of three neurotoxin based mouse models of PD, 3) the characterization of the innate immune response in PD through the toll-like receptor signaling pathways 4) evaluation of the effects of chronic systemic inflammation on both resident and infiltrating immune cells in the CNS. In 2012, Dr. Santoro attained his Pharm.D. in chemistry and pharmaceutical technology (5-year program) at the University of Calabria (Italy), during which he undertook an internship at King’s College London (SGDP Centre) and worked for over a year on a rat model of stroke.
-
Ansuman Satpathy, MD, PhD
Associate Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
-
Birgitt Schuele
Associate Professor (Research) of Pathology and, by courtesy, of Neurology and Neurological Sciences
Current Research and Scholarly InterestsThe Schuele lab focuses on neurogenetics, human stem cell modeling, and gene therapy approaches to uncover disease mechanisms and pathways involved in neurodegeneration in Parkinson's, Alzheimer's disease and related disorders.
-
Robert W. Shafer
Professor (Research) of Medicine (Infectious Diseases) and, by courtesy, of Pathology
Current Research and Scholarly InterestsMy group’s research is on the mechanisms and consequences of virus evolution with a focus on HIV therapy and drug resistance. We maintain a public HIV drug resistance database (http://hivdb.stanford.edu) as a resource for HIV drug resistance surveillance, interpreting HIV drug resistance tests, and HIV drug development. Our paramount goal is to inform HIV treatment and prevention policies by identifying the main factors responsible for the emergence and spread of drug resistance.
-
Hua Shan
Professor of Pathology
BioDr. Shan specializes in providing blood transfusion and apheresis treatment to patients with diverse medical problems. She has been practicing transfusion medicine for over thirty years. Dr. Shan served as the Medical Director of Transfusion Service at Stanford Medical Center from 2015 to 2026. Dr. Shan has also been leading research and education programs in the fields of transfusion safety, optimizing clinical blood transfusion practice and blood availability.
